Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.

doi:10.1097/00007691-199302000-00002

Back to search

Article

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.

Therapeutic drug monitoring - 1 Feb 1993

Sindrup S H, Brøsen K, Hansen M G, Aaes-Jørgensen T, Overø K F, Gram L F

Abstract excerpt

The relationship between the metabolism of the selective serotonin reuptake inhibitor citalopram and the sparteine and mephenytoin oxidation polymorphisms was studied in 24 healthy male volunteers, constituting panels of extensive metabolizers of sparteine and mephenytoin (n = 10), poor metaboliz...

Topics

Citalopram
Humans
Male
Mephenytoin
Oxidation-Reduction
Phenotype
Polymorphism, Genetic
Sparteine

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.